Follow
Pamela McCombe
Pamela McCombe
Verified email at uq.edu.au
Title
Cited by
Cited by
Year
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
JA Cohen, AJ Coles, DL Arnold, C Confavreux, EJ Fox, HP Hartung, ...
The Lancet 380 (9856), 1819-1828, 2012
12512012
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
AJ Coles, CL Twyman, DL Arnold, JA Cohen, C Confavreux, EJ Fox, ...
The lancet 380 (9856), 1829-1839, 2012
12442012
Gender differences in autoimmune disease
ST Ngo, FJ Steyn, PA McCombe
Frontiers in neuroendocrinology 35 (3), 347-369, 2014
10382014
Chronic inflammatory demyelinating polyradiculoneuropathy
PA McCombe, JD Pollard, JG McLeod
Brain 110 (1), 617-1630, 1987
5641987
Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis
JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ...
Jama 321 (2), 175-187, 2019
4612019
Effects of gender in amyotrophic lateral sclerosis
PA McCombe, RD Henderson
Gender medicine 7 (6), 557-570, 2010
4212010
Defining secondary progressive multiple sclerosis
J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ...
Brain 139 (9), 2395-2405, 2016
3912016
Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology
W Van Rheenen, RAA Van Der Spek, MK Bakker, JJFA Van Vugt, PJ Hop, ...
Nature genetics 53 (12), 1636-1648, 2021
2752021
Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings
AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ...
Neurology 89 (11), 1117-1126, 2017
2752017
Apoptosis in the nervous system in experimental allergic encephalomyelitis
MP Pender, KB Nguyen, PA McCombe, JFR Kerr
Journal of the neurological sciences 104 (1), 81-87, 1991
2721991
The role of immune and inflammatory mechanisms in ALS
P A McCombe, R D Henderson
Current molecular medicine 11 (3), 246-254, 2011
2392011
Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy
E Havrdova, DL Arnold, JA Cohen, HP Hartung, EJ Fox, G Giovannoni, ...
Neurology 89 (11), 1107-1116, 2017
2292017
Hypermetabolism in ALS is associated with greater functional decline and shorter survival
FJ Steyn, ZA Ioannides, RPA Van Eijk, S Heggie, KA Thorpe, A Ceslis, ...
Journal of Neurology, Neurosurgery & Psychiatry 89 (10), 1016-1023, 2018
2062018
Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis
VG Jokubaitis, T Spelman, T Kalincik, J Lorscheider, E Havrdova, ...
Annals of neurology 80 (1), 89-100, 2016
2052016
Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms
JM Greer, PA McCombe
Journal of neuroimmunology 234 (1-2), 7-18, 2011
2052011
Sexual dimorphism in autoimmune disease
PA McCombe, JM Greer, IR Mackay
Current molecular medicine 9 (9), 1058-1079, 2009
2022009
Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis
T Kalincik, D Horakova, T Spelman, V Jokubaitis, M Trojano, A Lugaresi, ...
Annals of Neurology 77 (3), 425-435, 2015
1862015
The effect of ageing on human lymphocyte subsets: comparison of males and females
J Yan, JM Greer, R Hull, JD O'Sullivan, RD Henderson, SJ Read, ...
Immunity & Ageing 7, 1-10, 2010
1772010
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
T Kalincik, JWL Brown, N Robertson, M Willis, N Scolding, CM Rice, ...
The Lancet Neurology 16 (4), 271-281, 2017
1712017
The peripheral neuropathy of vitamin B12 deficiency
PA McCombe, JG McLeod
Journal of the neurological sciences 66 (1), 117-126, 1984
1501984
The system can't perform the operation now. Try again later.
Articles 1–20